在心脏病发作后进行的干细胞治疗减少了心脏病的发病率和在一次重大试验中的住院率。 A stem cell treatment given after heart attacks reduced heart failure and hospitalizations in a major trial.

《BMJ》出版的大规模第3阶段试验发现,在心脏病发作后数日内提供豆子导线导导出的超感性裂变干细胞可大大降低心脏病发作和相关住院的风险。 A large phase 3 trial published in The BMJ finds that giving umbilical cord-derived mesenchymal stem cells within days of a heart attack significantly reduces the risk of heart failure and related hospitalizations. 在396名伊朗病人中,接受干细胞注射的人的心脏病发病率、医院重新接纳率较低,在33个月中将心血管疾病综合在一起,心脏功能在6个月中改善。 Among 396 Iranian patients, those receiving stem cell infusions had lower rates of heart failure, hospital readmissions, and combined cardiovascular events over 33 months, with improved heart function at six months. 在总体死亡率或心血管死亡率方面没有显著差异。 No significant differences were seen in overall or cardiovascular death rates. 治疗在防止心脏病发作方面显示出希望,但结果可能不适用于老年人或妇女,因为学习的局限性。 The therapy showed promise in preventing heart failure progression, though results may not apply to older adults or women due to study limitations. 研究人员呼吁进行更大规模的试验,以证实调查结果并了解这一机制。 Researchers call for larger trials to confirm findings and understand the mechanism.